BT13, a smaller molecule, is able to cross the blood-brain barrier -- and therefore could be more easily administered as a treatment, if shown to be beneficial in further clinical trials.

In a new study, researchers from the University of Helsinki, in Finland, have homed in on a molecule, called BT13, which they believe has potential as a therapeutic for Parkinson’s disease.